Merck said it’s stopping development of both of its COVID-19 vaccine candidates.
The candidates in studies “were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines,” the New Jersey-based company said in a statement on Jan. 25.
